Measuring How Well Lutetium Treatment Works for Advanced Prostate Cancer
Part of Cancer clinical trials.
This study tracks how well a radioactive treatment (lutetium-PSMA) works for men with advanced prostate cancer that no longer responds to hormone therapy. Researchers will use imaging scans to see which patients benefit most and how quickly the treatment takes effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castration-resistant prostate cancer (cancer that has spread and stopped responding to hormone therapy)
- You have already received at least two full cycles of 177Lu-PSMA treatment (a radioactive injection therapy)
- You are willing to allow your medical records and scan images to be used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
This study follows men with advanced prostate cancer who are receiving a new radioactive treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how well the treatment works in everyday practice, and to gather information on safety and effectiveness.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
Hear when a new Therapy-Associated Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.